Endovascular Repair of Infrarenal Abdominal Aortic Aneurysm Using Endovascular Stent Graft
Investigational drug(s) / intervention(s)
Implantation with Minos Stent graft
Implantation with Minos Stent graft: Treatment of subjects diagnosed with abdominal aortic aneurysm using the low-profile Minos Abdominal Aortic Stent-Graft and Delivery System. Follow up as per institutional standard of care.
Study summary
The Minos™ Abdominal Aortic Stent-Graft and Delivery System is a medical device designed to treat abdominal aortic aneurysms using a minimally invasive procedure. The device is placed inside the aorta through blood vessels, usually accessed through small incisions in the groin. The goal of this observational study is to collect short-, medium- to long-term safety and performance data of the Minos™ stent-graft in everyday medical practice (real-world settings). The aim is to study about 200 patients worldwide and at least 30 patients in European hospitals.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Diagnosis of infrarenal abdominal aortic aneurysm
* Plan to treat with Minos Abdominal Aortic Stent-Graft and Delivery System
* Voluntary participation and completion of Informed Consent Form, with willingness to participate in follow-up to 5 years post-procedure
Exclusion Criteria:
* Subjects in whom use of the Minos™ Abdominal Aortic Stent-Graft and Delivery System is contraindicated, as follows:
* Severe stenosis or calcification near the aneurysm, leading to difficulty in achieving apposition of vessel wall and stent graft.
* Difficult access due to severe stenosis or tortuosity in the iliac artery or femoral artery.
* Subjects with ruptured aneurysm or acute aneurysm.
* Subjects with an infectious aneurysm.
* Those who are allergic to contrast agents or unable to tolerate contrast agents due to renal insufficiency.
* Patients with severe coagulation disorder and/or high risk of postoperative hemorrhage.
* Aneurysmal neck angulation greater than 60°.
* Patients with blood supply to vital organs originating from the aneurysmal sac.
* Patients with other comorbidities and whose life expectancy does not exceed one year.
* Subjects with connective tissue diseases, such as Marfan syndrome.
* Minors and pregnant women.
* Subjects who are allergic to nitinol.
* Subjects who are considered not suitable for treatment with stent graft.
Primary outcome measure(s)
Technical success rate at 12 months — 12 months Technical success at 12 months is defined as accurate positioning of stent graft, normal stent shape, no distortion, bending, stenosis and occlusion, and no accidental coverage of internal iliac artery or visceral artery, the absence of aneurysm rupture, continuous type I and III endoleaks after operation, aneurysm enlargement (aneurysm diameter increased by more than 5mm), secondary intervention due to endoleak, stent occlusion or migration, including open surgery and endovascular surgery. Expected secondary interventions will not be included in the analysis.
Trial sites (16)
Facility
City
Region
Status
The Second Hospital of Lanzhou University
Lanzhou
Gansu
Recruiting
Meizhou People's Hospital
Meizhou
Guangdong
Recruiting
The University of Hong Kong - Shenzhen Hospital
Shenzhen
Guangdong
Recruiting
Hunan Provincial People's Hospital
Changsha
Hunan
Recruiting
Xiangtan Central Hospital
Xiangtan
Hunan
Recruiting
Yueyang Central Hospital
Yueyang
Hunan
Recruiting
Zibo Central Hospital
Zibo
Shandong
Recruiting
TEDA International Cardiovascular Hospital
Binhai
Tianjin Municipality
Recruiting
Kunming Yan'an Hospital
Kunming
Yunnan
Recruiting
Fuwai Hospital
Beijing
China
Recruiting
Klinikverbund Allgäu
Immenstadt im Allgäu
Allgäu
Recruiting
Universitätsklinikum Münster (UKM)
Münster
Germany
Recruiting
"G. Gennimatas" Thessaloniki General Hospital
Thessaloniki
Greece
Recruiting
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (ASST Spedali Civili di Brescia)
Brescia
Italy
Not Yet Recruiting
Erasmus MC
Rotterdam
Netherlands
Recruiting
Hospital Universitari de Girona Doctor Josep Trueta
Girona
Catalonia
Not Yet Recruiting
More Shanghai MicroPort Endovascular MedTech(Group)Co., Ltd trials in Germany
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.